Profound Medical/$PROF
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Profound Medical
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.
Ticker
$PROF
Sector
Primary listing
Employees
162
Headquarters
Mississauga, Canada
Website
Profound Medical Metrics
BasicAdvanced
$199M
-
-$1.41
0.39
-
Price and volume
Market cap
$199M
Beta
0.39
52-week high
$8.95
52-week low
$3.76
Average daily volume
255K
Financial strength
Current ratio
12.525
Quick ratio
11.016
Long term debt to equity
6.772
Total debt to equity
7.093
Profitability
EBITDA (TTM)
-40.694
Gross margin (TTM)
70.77%
Net profit margin (TTM)
-264.44%
Operating margin (TTM)
-256.27%
Effective tax rate (TTM)
-0.60%
Revenue per employee (TTM)
$100,000
Management effectiveness
Return on assets (TTM)
-34.91%
Return on equity (TTM)
-67.12%
Valuation
Price to revenue (TTM)
10.348
Price to book
4.12
Price to tangible book (TTM)
4.13
Price to free cash flow (TTM)
-4.333
Free cash flow yield (TTM)
-23.08%
Free cash flow per share (TTM)
-1.272
Growth
Revenue change (TTM)
50.73%
Earnings per share change (TTM)
25.36%
3-year revenue growth (CAGR)
34.06%
3-year earnings per share growth (CAGR)
0.76%
10-year earnings per share growth (CAGR)
-11.98%
What the Analysts think about Profound Medical
Analyst ratings (Buy, Hold, Sell) for Profound Medical stock.
Profound Medical Financial Performance
Revenues and expenses
Profound Medical Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Profound Medical stock?
Profound Medical (PROF) has a market cap of $199M as of March 14, 2026.
What is the P/E ratio for Profound Medical stock?
The price to earnings (P/E) ratio for Profound Medical (PROF) stock is 0 as of March 14, 2026.
Does Profound Medical stock pay dividends?
No, Profound Medical (PROF) stock does not pay dividends to its shareholders as of March 14, 2026.
When is the next Profound Medical dividend payment date?
Profound Medical (PROF) stock does not pay dividends to its shareholders.
What is the beta indicator for Profound Medical?
Profound Medical (PROF) has a beta rating of 0.39. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.